As of Feb 22
| -0.60 / -1.44%|
The 22 analysts offering 12-month price forecasts for GlaxoSmithKline have a median target of 45.11, with a high estimate of 51.75 and a low estimate of 38.02. The median estimate represents a +9.94% increase from the last price of 41.03.
The current consensus among 23 polled investment analysts is to Hold stock in GlaxoSmithKline. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.